Literature DB >> 23103618

Population pharmacokinetics of modafinil acid and estimation of the metabolic conversion of modafinil into modafinil acid in 5 major ethnic groups of China.

Ke-hua Wu1, Tao Guo, Chen-hui Deng, Zheng Guan, Liang Li, Tian-yan Zhou, Wei Lu.   

Abstract

AIM: To describe the population pharmacokinetic profile of modafinil acid and to compare the extent of metabolism of modafinil into modafinil acid in 5 major ethnic groups (Han, Mongolian, Korean, Uygur, and Hui) of China.
METHODS: In a multi-center, open-label, single dose clinical trial, 49 healthy volunteers from the 5 ethnic groups received 200 mg of modafinil orally. Blood samples for pharmacokinetic evaluation of modafinil and modafinil acid were drawn before and at different time after the administration. Systematic population pharmacokinetic (PopPK) modeling for modafinil acid was conducted, integrating with our previous PopPK model for modafinil. The influence of ethnicity, gender, height, body weight and body mass index (BMI) was estimated. The extent of metabolism of modafinil into modafinil acid, expressed as the relative conversion fraction, was estimated and compared among the 5 ethnic groups.
RESULTS: When combined with the PopPK model of modafinil, the concentration of modafinil acid versus time profile was best described with a one-compartment model. The typical clearance and volume of distribution for modafinil acid were 4.94 (l/h) and 2.73 (l), respectively. The Korean group had 25% higher clearance, and the Uygur and Hui groups had 12% higher clearance than the Han group. The median for the relative conversion fraction was 0.53 for Koreans, and 0.24 for the other 4 ethnicities.
CONCLUSION: Ethnicity has significant influence on the clearance of modafinil acid. When patients in the 5 ethnic groups are administered drugs or prodrugs catalyzed by esterases and/or amidases, the variability in the extent of drug metabolism should be considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103618      PMCID: PMC4011351          DOI: 10.1038/aps.2012.124

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  14 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

Review 2.  Lessons learned from marketed and investigational prodrugs.

Authors:  Peter Ettmayer; Gordon L Amidon; Bernd Clement; Bernard Testa
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

Review 3.  Prodrugs: design and clinical applications.

Authors:  Jarkko Rautio; Hanna Kumpulainen; Tycho Heimbach; Reza Oliyai; Dooman Oh; Tomi Järvinen; Jouko Savolainen
Journal:  Nat Rev Drug Discov       Date:  2008-03       Impact factor: 84.694

4.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

Authors:  Jae Eun Ahn; Mats O Karlsson; Adrian Dunne; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-08-07       Impact factor: 2.745

5.  Population pharmacokinetics of modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui healthy subjects determined by nonlinear mixed-effects modeling.

Authors:  Guo Tao; Zhao Longshan; Wu Kehua; Xia Dongya; Lu Wei; Guan Zheng; Deng Chenhui
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

6.  Drug metabolite kinetics: noncompartmental analysis.

Authors:  M Weiss
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

7.  Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat.

Authors:  Jonathan P Wisor; William C Dement; Lisa Aimone; Michael Williams; Donna Bozyczko-Coyne
Journal:  Pharmacol Biochem Behav       Date:  2006-11-28       Impact factor: 3.533

8.  Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

Authors:  Thorsten Lehr; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Andreas Raschig; Hans Guenter Schaefer; Charlotte Kloft
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

Review 9.  Modafinil: a review of neurochemical actions and effects on cognition.

Authors:  Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

10.  Analysis of East Asia genetic substructure using genome-wide SNP arrays.

Authors:  Chao Tian; Roman Kosoy; Annette Lee; Michael Ransom; John W Belmont; Peter K Gregersen; Michael F Seldin
Journal:  PLoS One       Date:  2008-12-05       Impact factor: 3.240

View more
  2 in total

1.  Pharmacometrics: a quantitative tool of pharmacological research.

Authors:  Qing-shan Zheng; Lu-jin Li
Journal:  Acta Pharmacol Sin       Date:  2012-11       Impact factor: 6.150

2.  Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?

Authors:  Olusola Olafuyi; Nikita Parekh; Jacob Wright; Jennifer Koenig
Journal:  Pharmacol Res Perspect       Date:  2021-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.